Skip to main content
New GLP-1 protocol guide just published Read →

Delta-Sleep-Inducing Peptide (DSIP): A Review

Graf MV, Kastin AJ

Neuroscience & Biobehavioral Reviews/1984

Background

By the early 1980s, more than a decade of research had accumulated on delta sleep-inducing peptide (DSIP) following Monnier’s original discovery. Graf and Kastin’s comprehensive review synthesized this literature, cataloging DSIP’s behavioral, endocrine, neurochemical, and metabolic effects across dozens of animal and limited human studies.

This review became an essential reference point for understanding DSIP as a pleiotropic neuropeptide — one whose actions extend well beyond the sleep/wake axis into HPA axis regulation, thermoregulation, and antioxidant function.

Key Findings

Sleep Effects:

  • DSIP consistently promotes delta (slow-wave) sleep in rats, cats, and rabbits when administered IV or ICV
  • Effects are specific to NREM sleep architecture; REM sleep is modestly enhanced in some preparations
  • SC and intranasal administration produce weaker effects, likely due to peptide degradation before CNS access

Neuroendocrine Modulation:

  • DSIP attenuates stress-induced elevations in ACTH and corticosterone in rodents
  • Facilitates GH secretion — particularly the nocturnal GH pulse — by potentiating GHRH activity at the pituitary level
  • May modulate LH secretion, with sex-dependent effects in some models

Neuroprotective / Antistress Properties:

  • DSIP reduces stress-induced hyperalgesia and behavioral signs of learned helplessness
  • Demonstrates antioxidant activity in neuronal cell preparations
  • Attenuates alcohol and opioid withdrawal severity in animal models — an early clue to its broader anti-stress pharmacology

Pharmacokinetics:

  • Rapid peripheral degradation by serum enzymes limits bioavailability
  • CNS penetration is higher than predicted for its molecular weight, possibly via specific transport
  • Synthetic analogs with greater protease resistance were subsequently developed

Clinical Significance

This systematic review established DSIP as a multifunctional neuropeptide with relevance to:

  1. Sleep disorders: Slow-wave sleep enhancement without sedation suggests potential for non-benzodiazepine insomnia treatment
  2. Stress and HPA dysregulation: ACTH/cortisol buffering relevant to burnout, PTSD, and adrenal fatigue contexts
  3. Withdrawal states: Attenuation of opioid and alcohol withdrawal opens addiction medicine applications
  4. GH axis support: DSIP-mediated enhancement of nocturnal GH pulses is relevant to recovery and body composition

Limitations

  • The majority of evidence is from animal models; controlled human studies are sparse
  • Receptor identification was incomplete at the time of this review — DSIP’s mechanism remains incompletely characterized
  • Variability in synthetic peptide preparations complicates cross-study comparisons
  • CNS vs. peripheral site of action debated across studies

Compounds Studied

Related Conditions

Related Studies